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BACKGROUND 
Fatigue is frequently reported by patients with 
IBD, despite disease remission.  However, few 
previous intervention trials have specifically 
assessed this symptom.  
Main fatigue outcomes:  
• Significant deterioration in FACIT-F 
score (more fatigue) (95%CI: -8.6 to (-
0.7); p=0.02) with omega-3 fish oil 
• Significant reduction in fatigue in 
exercise groups, measured by IBD-F 
Section I score (95%CI: -3.8 to -0.2; p = 
0.03) 
CONCLUSIONS 
The apparent worsening of fatigue with fish 
oil is unexplained. Exercise and fish oil, 
singly or in combination, were shown to be 
safe and generally well-tolerated in IBD 
patients. There was no evidence of adverse 
exercise-related effects on gut-related 
symptoms, and some evidence of 
improvement in fatigue. Hence, regular 
moderate-vigorous exercise may provide 
self-management options in IBD-related 
fatigue. 
Figure 2: Frequency of adverse effects from exercise 
and/or fish oil supplement in IBD patients. N & V: 
nausea and vomiting.  
AIM 
To test the effects on fatigue in  
Inflammatory Bowel Disease (IBD) patients 
from: 
• Individual advice to increase physical 
activity (PA) and/or  
• Supplementation with omega-3 fatty 
acids. 
METHODS 
Design: Randomised controlled 2x2 factorial 
pilot study comparing change-from-baseline 
scores in intervention and control groups.  
Primary outcome: Change in FACIT-F 
(Functional Assessment of Chronic Illness 
Therapy - Fatigue) score. 
Main secondary outcomes: Change in fatigue 
survey scores including IBD-Fatigue (IBD-F); PA 
by monitors (Actigraph, Pensacola, US); 
adverse effects.  
Eligibility: IBD remission; ≤2 portions oily 
fish/week; ≤ 60 minutes moderate-vigorous 
PA/week; no comorbidities causing fatigue; no 
depression.  
 Intervention: 
Control: Placebo supplement; diet diary. 
Exercise and placebo: Consultation (15 minutes) 
with personal trainer; activity and diet diary. 
Diet treatment:  Fish oil supplement (2.97g per 
day omega-3, “Take Omega 3”©, Edinburgh, UK); 
diet diary. 
Diet and Exercise: Consultation with personal 
trainer (15 minutes); activity and diet diary. 
All patients received follow-up support (email, 
telephone). 
Adverse events:  
One treatment-related event (in exercise group); 
neither exercise nor fish oil were associated with 
likelihood of occurrence of adverse effects, 
including gastrointestinal symptoms. 
• No significant interactions between effects of 
exercise and fish oil on fatigue 
• No consistent trends in fatigue or PA levels 
across the various measures between the 
four treatment groups 
Table: Main fatigue outcomes: (*) Figures for 
patients with UC and unclassified IBD. (**) Figures for 
patients with Crohn's and unclassified IBD. (+) Odds 
Ratio (95% CI) reported. (++) Variable analysed on log 
scale. Ratio (95% CI) reported. FACIT-F: Functional 
Assessment of Chronic Illness-Fatigue; SCCI: Simple 
Clinical Colitis Index; HBI: Harvey Bradshaw Index; 
MVPA: Moderate-Vigorous Physical Activity; CRP: C-
reactive protein; IBD-F: IBD-Fatigue score; MFI: 
Multidimensional Fatigue Inventory; IBDQ: 
Inflammatory Bowel Disease Quality of Life 




Figure 1: Enrolment of IBD patients and completion 
of protocol. 
 
Baseline: Similar parameters for gender, 
age, disease location, past IBD activity, 
level of PA, or FACIT-F.  
 
